期刊文献+

慢性肾脏病诱导骨骼肌萎缩的发病机制 被引量:2

Muscle wasting associated chronic kidney disease
下载PDF
导出
摘要 慢性肾脏病(CKD)患者常伴难纠正的进行性蛋白-能量消耗(PEW),临床主要表现骨骼肌萎缩。肌萎缩的发病机制很复杂,常由多因素共同作用所致。既往研究认为食欲减退、泛素-蛋白酶体系活化及细胞内胰岛素/胰岛素样生长因子1/磷脂酰肌醇激酶/蛋白激酶B信号通路受损是导致肌萎缩的主要原因。然而随着近年大量深入研究,发现炎症反应、代谢性酸中毒、激素代谢紊乱和肌抑素表达增加等因素在肌萎缩发生发展中也起着不可忽视的作用,但其中部分作用机制尚未完全阐明,需深入探索,以寻找切实有效的干预靶点,改善CKD患者临床预后。 The patients with chronic kidney disease usually have progressive protein-energy waste, which increases the morbidity and mortality. Most body stores of protein are in skeletal muscle, the protein depletion presents itself as loss of muscle mass, or muscle atrophy. The pathogenesis of muscle wasting is very complex, which is usually caused by muhifactors. Previous studies showed that anorexia, activation of the ATP-dependent ubiquitin-proteasome system and defects in insulin/insulin-like growth factor 1 (IGF-1)/PI3K/Akt intraeellular signaling processes accelerated muscle protein degradation, deereased protein synthesis, and caused the muscle atrophy. Recent studies found that elevated levels of eytokines, metabolic acidosis, increased levels of myostatin and glucoeortieoid also play an important role in causing muscle wasting. Some of their mechanisms are not clear,and more studies are needed for finding effective treatment to improve the outcome of patients with CKD.
出处 《肾脏病与透析肾移植杂志》 CAS CSCD 北大核心 2013年第2期158-161,共4页 Chinese Journal of Nephrology,Dialysis & Transplantation
关键词 慢性肾脏病 骨骼肌萎缩 发病机制 chronic kidney disease muscle wasting pathogenesis
  • 相关文献

参考文献26

  • 1Kalantar-Zadeh K, Ikizler TA, Block G, et al. Malnutrition- inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis,2003,42 (5) :864-881.
  • 2Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int,2008 ,73 :391-398.
  • 3Combe C, Chauveau P, Laville M, et al. Influence of nutritional factors and hemodialysis adequacy on the survival of 1,610 French patients. Am J Kidney Dis,2001,37 (1 Suppl 2) :S81-S88.
  • 4Lacson E Jr, Ikizler TA, Lazarus JM, et al. Potential impact of nutritional intervention on end-stage renal disease hospitalization, death, and treatment costs. J Ren Nutr,2007,17 ( 6 ) : 363-371.
  • 5Mitch WE,Goldberg AL. Mechanisms of muscle wasting:The role of the ubiquitin-proteasome pathway. N Engl J Med, 1996,335 ( 25 ) : 1897-1905.
  • 6Cheung W, Yu PX, Little BM. Role of leptin and melanocortin signaling in uremia-associated caehexia. J Clin Invest,2005,115 (6) : 1659-1665.
  • 7Yoshimoto A, Mori K, Sugawara A, et al. Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Plasma ghrelin and desacyl ghrelin concentration in renal failure. J Am Soc Nephro1,2002,13 ( 11 ) :2748-2752.
  • 8Cohen S,Brault JJ, Gygi SP, et al. During muscle atrophy, thick, but not thin, filament components are degraded by MuRFl-dependent ubiquitylation. J Cell Bio, 2009,185 ( 6 ) : 1083-1095.
  • 9Lee SW, Dai G, Hu Z, et al. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol, 2004, 15 ( 6 ) : 1537-1545.
  • 10Brunelli SM, Thadhani R, Ikizler TA, et al. Thiazolidinedione use is associated with better survival in hemodialysis patients with non- insulin dependent diabetes. Kidney Int,2009,75 (9) :961-968.

二级参考文献13

  • 1Ortoft G,Andreassen TT,Oxlund H.Growth hormone can reverse glucocorticoid-induced low bone turnover on cortical but not on cancellous bone surfaces in adult Wistar rats.Bone,2005,36:123-133.
  • 2Kim HJ.New understanding of glucocorticoid action in bone cells.BMB Rep,2010,43:524-529.
  • 3Weinstein RS,Chen JR,Powers CC,et al.Promoting of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids.J Clin Invest,2002,109:1041-1048.
  • 4Angeli A,Guglielmi G,Dovio A,et al.High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy:a cross-sectional outpatient study.Bone,2006,39:253-259.
  • 5Pennisi P,Trombetti A,Rizzoli R.Glucocorticoid-induced osteoporosis and its treatment.Clin Orthop Relat Res,2006,443:39-47.
  • 6Van Staa TP,Cooper C,Leufkens HG,et al.Children and the risk of fractures caused by oral corticosteroids.J Bone Miner Res,2003,18:913-918.
  • 7Macrae VE,Ahmed SF,Mushtaq T,et al.IGF-1 signalling in bone growth:inhibitory actions of dexamethasone and IL1beta.Growth Horm IGF Res,2007,17:435-439.
  • 8Celiker R,Arslan S.Comparison of serum insulin-like growth factor-1 and growth hormone levels in osteoporotic and non-osteoporotic post-menopausal women.Rheumatol Int,2000,19:205-208.
  • 9Civitelli R,Ziambaras K.Epidemiology of glucocorticoidinduced osteoporosis.J Endocrinol Invest,2008,31:2-6.
  • 10Canalis E,Bilezikian JP,Angeli A,et al.Perspectives on glucocorticoid-induced osteoporosis.Bone,2004,34:593-598.

共引文献10

同被引文献12

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部